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Summary: In patients with severe traumatic brain injury, the early healing of fractures is accompanied by hypertro-
phic callus formation or heterotopic ossifications, which might even result in ankylosis of the affected joints.
Analysis of the sera of patients with traumatic brain injury revealed post-traumatic dynamic changes of basic
fibroblast growth factor immunoreactivity, similar to those observed during fracture healing associated with en-
hanced osteogenesis. The aim of this study was to determine whether such changes in basic fibroblast growth
factor concentrations could be related to the phenomenon of enhanced osteogenesis. Basic fibroblast growth factor
immunoreactivity was determined (using an IEMA kit) in the sera of patients with traumatic brain injury and bone
fractures (n = 8) and in the sera of patients with either traumatic brain injury alone (n = 10) or bone fractures
alone (n = 7), and the effects of these sera on L929 fibroblast growth were analysed in vitro. The results did not
prove a causative relationship between the changes of basic fibroblast growth factor immunoreactivity and in vitro
growth prompting effects of the sera. However, it is apparent that, in addition to changes in the growth-promoting
activity and basic fibroblast growth factor concentration of serum, other as yet unknown post-traumatic changes
can cause enhanced osteogenesis.
Introduction
The phenomenon of excessive callus formation in pa- derlying this phenomenon are still unknown, it seems
tients with traumatic brain injury and fractures of long that traumatic brain injury is accompanied by an
bones and large joints has often been described and is increased amount of humoral growth stimulating factors
well documented (1-^4). Although the mechanisms un- in the serum, which may enhance osteogenesis (5). The
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growth factor that seems most likely to fulfil this role is
basic fibroblast growth factor. Basic fibroblast growth
factor was purified from bovine pituitary gland tissue by
Gospodarowicz in 1975 (6). The activity of this growth
factor in vivo is mainly described as induction of angio-
genesis and stimulation of wound healing, while in vitro
basic fibroblast growth factor influences the prolifera-
tion and differentiation of a wide variety of cells, such
as fibroblasts, chondroblasts, osteoblasts, adrenocortical
cells, etc. (7-10). Altough the physiological role of ba-
sic fibroblast growth factor in bone metabolism still re-
mains to be defined, its biological effects suggest that it
may be an important regulator of bone growth and frac-
ture healing. The most recent findings, using a novel
human basic fibroblast growth factor immunoassay,
show a change of basic fibroblast growth factor irnmu-
noreactivity in the sera of patients with traumatic brain
injury alone or combined with the bone fractures, as
well as in the sera of patients with bone fractures only
(11). However, it is not certain whether the observed
post-traumatic dynamic changes of basic fibroblast
growth factor immunoreactivity have an influence on
the cell growth promoting activity of the serum. The aim
of this study was to test the possibility that basic fibro-
blast growth factor is one of the unidentified humoral
factors that cause enhanced osteogenesis in patients with
traumatic brain injury. Post-traumatic dynamic changes
of basic fibroblast growth factor immunoreactivity in the
sera of patients with traumatic brain injury alone or
combined with the bone fractures, as well as in the sera
of patients with bone fractures only, were therefore com-
pared with the effects of these sera on the growth of
L929 cells in vitro.
Materials and Methods
Subjects
Blood specimens were obtained from thirty-four subjects who were
assigned to one of the following four groups.
Group I comprised 8 patients with traumatic brain injury and
fractures of long bones or large joints. Six of the patients were
male, and two female. The mean age (median value) was 18
years. Except for one patient the cause of injury was a traffic
accident. All the patients were in coma from 3 to 20 days
(average of 9 days). Five patients had intracerebral and/or in-
tracranial haematomas, while three had diffuse oedema. Only
one of the patients had to be craniotomised, while three patients
required surgery for facial fractures. Six of the patients had
cranial or facial fractures. All of them had fractures of the
femur, one on both sides. Two patients also had fractures of the
pelvis. The first callus formation occurred between the second
and the fourth week after injury, and it was extended in every
patient. One patient had heterotopic ossifications around the
elbow and on the lateral femur condyl after Steinmann nail
extension, and one patient had heterotopic ossifications in the
small pelvis after a fracture of the iliac wing.
Group II included 10 patients with traumatic brain injury only, 8
male and two females. The median age value was 23.5 years. Nine
of the patients were victims of traffic accidents, while one had
fallen. All had either intracerebral or subdural haematoma or both.
Four patients had to be craniotomised. The average coma lasted 11
days, while one patient died after 37 days of coma. Five of the
patients had transitory neurological deficits, i. e. hemiparesis. All
the surviving patients recovered.
Group III included 7 patients with fractured of long bones or large
joints only. Five patients were male and two female. The age range
was 18 to 64 years (median 26 years). They were mostly injured
in traffic accidents. Six of the patients had fractures of the femur,
one on both sides. One patient had a dislocation fracture of the
elbow, while another one had fractures of both acetabula. The con-
solidation of the femur fractures and the fractures of the pelvis
lasted about 12 weeks on average. No pathologically increased cal-
lus formation and no heterotopic ossifications were observed in
these patients.
The patients of all three groups received sc. injections of heparin
(2500-5000 I.U., depending on the body weight) daily during
their stay in hospital (on the average for 4-6 weeks). Antibiotics
were mostly given as prophylactics, analgesics were used occasion-
ally, while steroids were not applied.
Group IV included 9 normal, healthy subjects, 5 male and 4 fe-
male. The age range was 20 to 45 years (median 24 years).
Serum samples
Sera were prepared from blood samples (5—6 ml) taken from the
patients, and the healthy subjects, between 8 and 10 a. m., at regu-
lar time intervals after the traumatic event. Blood was taken weekly
after the injury, and after the release of patients from the hospital
at intervals of two weeks for the following three months. The first
samples were taken in the first two to four days after the accident.
Blood samples were centrifuged within one hour at + 4 °C for 10
min at 500 g. Supernatants were collected, and their aliquots were
immediately frozen and stored at —30 °C.
Determination of basic fibroblast growth factor
immunoreactivity
Basic fibroblast growth factor immunoreactivity was determined
with a human basic fibroblast growth factor immunoassay (Quare
tikine™ HS Assay, R&D Systems, Inc., Minneapolis, USA). This
assay employs the quantitative "sandwich" enzyme immunoassay
technique (IEMA) using alkaline phosphatase as an amplification
system. The assay is based on murine monoclonal antibodies
against recombinant human basic fibroblast growth factor. Analysis
of the serial dilution of recombinant human basic fibroblast growth
factor standards and of the pooled normal human sera enriched
with recombinant human basic fibroblast growth factor revealed
an intra-assay precision > 86% (i. e., variation < 14%) for three
measurements of high (> 15 ng/1) and low (< 2 ng/1) basic fibro-
blast growth factor-containing samples; The sera samples were ana-
lysed using two batches of the IEMA kit which showed an inter-
assay precision (for the standards and the chosen samples contain-
ing high or low basic fibroblast growth factor) greater than 73%
(for high basic fibroblast growth factor-containing samples, i.e.
> 15 ng/1, variation was < 20%). The serum samples used in the
study were analysed in duplicate and the means of the results
were calculated.
In vitro bioassay
The effects of sera from differently injured patients on cell growth
were analysed using a standard [3H]thymidine assay and mürine
fibroblasts (L929 cell line). The cells were harvested from semi,
confluent culture with 1 g/1 trypsin solution, then neutralized by
addition of culture medium supplemented with 50 ml/1 fetal calf
serum (GIBCO, Germany). After washing the cells twice (10 min
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at 250 #) with RPMI 1640 medium (without serum), the viability
of the cells was tested by trypan blue exclusion, the number of live
cells per litre of medium was adjusted to 4 Χ 1Ό8, and the cells
were seeded in vitro. The seeding density of the cells cultured in
96-well microcytoplates (Greiner, Frickenhausen, Germany) was
2 Χ 104 cells per culture. The cells were incubated without se-
rum for 24 hours at 37 °C in a humidified air atmosphere with
5% CO2. Afterwards, the sera obtained from the patients and
the normal subjects were added to the quadruplicates of cultures
at a final concentration of 10 ml/1 (this particular concentration
was chosen because preliminary testing showed higher serum
concentrations to be too toxic) and the cells were further incu-
bated for two days. The incorporation of [3H]thymidine (specific
activity 962 GBq/mmol, Amersham International, Pic., UK)
added at 4kBq (0.1 μόί) per culture was determined for the
last 24 hours of cell growth, after harvesting the cells with the
flow harvester (Skatron, Norway). Cell labelling was measured
in a β-counter (Wallac 1209 Rackbeta liquid scintillation counter,
Pharmacia, Sweden).
Statistics
The results were statistically evaluated by the Mann-Whitney U
test, and values of P < 0.05 were considered significant.
Results
In figure 1, post-traumatic changes of serum basic fibro-
blast growth factor in patients with bone fractures are
compared with the effects of the patient sera on L929
cell growth. Only a transient increase of basic fibroblast
growth factor immunoreactivity (on average three-fold
above the normal values) was observed in the second
week after injury (p < 0.02). Afterwards, the values for
the growth factor decreased to normal. Sera of these pa-
tients stimulated the cell growth more than the normal
human sera only during the first week after injury, while
the increase of basic fibroblast growth factor immunore-
activity during the second week was not accompanied
by a further increase of growth promoting activity. On
the contrary, from the second week onwards (until one
and half months after injury) the sera of patients with
bone fractures inhibited the cell growth (P < 0.05). Af-
ter the end of the second month, the inhibitory effect
of these sera was gradually lost. Although a slight but
significant (P < 0.05) increase of the basic fibroblast
growth factor concentration above normal was noticed
in the period from the 11th to the 14th week after injury,
the growth promoting activity of these sera was not
higher than the stimulating effect of normal sera
(P > 0.05). Sera obtained during the first week after in-
jury from the patients suffering from traumatic brain in-
jury only (without the bone fractures) also stimulated
(P < 0.05) the cell growth (fig. 2). Sera from the same
patients during the second post-traumatic week, how-
ever, inhibited the [3H]thymidine incorporation into
L929 cells (P < 0.05). Sera obtained later from patients
with traumatic brain injury did not affect L929 cell
growth differently from the control sera (for the entire
period, P > 0.05). Sera from patients with brain injury
also reached the maximal basic fibroblast growth factor
values during the second week after injury. Afterwards
the basic fibroblast growth factor concentration grad-
ually decreased. However, the values determined in the
sera of patients with traumatic brain injury were signifi-
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Fig, 1 Comparison of basic fibroblast growth factor (bFGF) im-
munoreactivity values in the sera of patients with bone fractures
only (N = 7) and the effects of the same sera on the growth of
L929 cells.
The results are presented as mean values ± SEM of basic fibroblast
growth factor (—x—) and the mean values ± SEM of [3H]thymi-
dine incorporation (—ο—) (counts per min and well) obtained for
the same sera (each serum was added at 10 mi/1 final concentration
to the quadruplicates of cultures). Range of the reference values
was 0.7-5.5 ng/1 for basic fibroblast growth factor and 1915-
2326 counts per min and well for the [3H]thymidine incorporation.
* Significant difference (P < 0.05 according to Mann-Whitney U
test) when compared with values obtained for healthy subjects
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Fig. 2 Comparison of basic fibroblast (bFGF) growth factor im-
munoreactivity values in the sera of patients with traumatic brain
injuries only (N = 10) and the effects of the same sera on the
growth of L929 cells.
The results are presented as mean values ± SEM of basic fibroblast
growth factor (-x-) and the mean values ± SEM of [3H]thymi-
dine incorporation (—ο—) (counts per min and well) obtained for
the same sera (each serum was added at 10 ml/1 final concentration
to the quadruplicates of cultures). Range of the reference values
was 0.7-5.5 ngA for basic fibroblast growth factor and 1915-
2326 counts per min and well for the [3H]thymidine incorporation.
* Significant difference (P < 0.05 according to Mann-Whitney U
test) when compared with values obtained for healthy subjects
(N = 9).
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cantly higher than normal values during the two months
(from the 1st until the 7-8th week after injury, for the
first three weeks P < 0.002, afterwards P < 0.02 or
0.05). The gradual decrease of the values for basic
fibroblast growth factor immunoreactivity was not ac-
companied by any changes in the effects of these sera
on the cell growth, i. e. from the second week onwards
these sera did not show any significant effect on the
[3H]thymidine incorporation into L929 cells
(P > 0.05).
Furthermore, as can be seen from the figure 3, sera from
patients with combined injury (traumatic brain injury
and the fractures of the long bones) resembled that from
patients in the previous two groups (figs 1, 2) in that
they stimulated L929 cell growth only during the first
week after injury (P < 0.05). At the same time, a large
increase of the serum basic fibroblast growth factor im-
munoreactivity was noticed (P < 0.002); a further
increase, however, was not associated with an increase
of growth promoting activity of the sera. Inhibition of
the [3H]thymidine incorporation into L929 cells was no-
ticed (P < 0.05) in the presence of the sera taken from
the patients with brain injury and bone fractures during
the second post-traumatic week (this was also noticed
for the previous groups). Marked changes of the growth
factor concentration in the sera of patients with trau-
matic brain injury and bone fractures were not associ-
ated with any particular changes in the effects of these
sera on cultured L929 cells (for the entire subsequent
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Fig. 3 Comparison of basic fibroblast growth factor (bFGF) im-
munoreactivity values in the sera of patients with traumatic brain
injuries and bone fractures (N = 8) and the effects of the same sera
on the growth of L929 cells.
The results are presented as mean values ± SEM of basic fibroblast
growth factor (-x-) and the mean values ± SEM of [3H]thymi-
dine incorporation (— —) (counts per min and well) obtained for
the same sera (each serum was added at 10 ml/1 final concentration
to the quadruplicates of cultures). Range of the reference values
was 0.7-5.5 ng/1 for basic fibroblast growth factor and 1915-
2326 counts per min and well for the [3H]thymidine incorporation.
* Significant difference (P < 0.05 according to Mann-Whitney U
test) when compared with values obtained for healthy subjects
(N = 9).
period, P > 0.05). Although significant differences in
basic fibroblast growth factor immunoreactivity have
been observed in the sera of differently injured patients
(11), no differences were observed between the effects
of these sera on the [3H]thymidine incorporation into
L929 cells (for all the time intervals and all the groups,
Discussion
The results do not indicate a causative relationship be-
tween the phenomenon of enhanced osteogenesis in pa-
tients with traumatic brain injury and the serum levels
of basic fibroblast growth factor immunoreactivity.
However, similar trends of post-traumatic changes of the
growth factor concentration in the sera of the patients
from all three groups and the effects of these sera on
L929 cells growth in vitro were noticed. Hence, it could
be assumed that basic fibroblast growth factor is one of
the major factors in the serum showing biological effects
on the L929 fibroblästs used for the [3H]thymidine in-
corporation bioassay. Such a conclusion seems to be
credible, since basic fibroblast growth factor influences
proliferation and differentiation in vitro of different
types of cells, such as fibroblästs, chondroblasts, osteo-
blasts, adrenocortical cells, etc. (7-10). Moreover, its
effects in vitro and in vivo indicate its involvement in
normal and enhanced osteogenesis. It has been shown
that basic fibroblast growth factor stimulates prolifera-
tion and differentiation of costal chondrocytes in vitro
(12), as well as chondrocyte proliferation and cartilage
healing in vivo (13). Furthermore, osteoblasts them-
selves synthesize basic fibroblast growth factor (7, 10,
14), while transient treatment with basic fibroblast
growth factor in vitro increases collagen synthesis in fer
tal rat osteoblasts (15). The hypothesis that basic fibro-
blast growth factor stored in the bone matrix has an in-
fluence on bone repair was proved (16), at least in a
part, by the finding of dramatic hyperostosis in rat fe-
murs after repeated intravenous administration of basic
fibroblast growth factor (17). On the other hand, a sig-
nificant transient increase of basic fibroblast growth
factor immunoreactivity in the brain areas damaged by
the traumatic brain injury or stroke was confirmed (18—
22). Hence, basic fibroblast growth factor is possibly
also released from the damaged brain tissue, but it is not
certain whether it could then modify the growth of cells
at the distant "target" organ (bone). On the other hand,
determination of the basic fibroblast growth factor val-
ues in serum (as well as its purification) is difficult,
since the growth factor is present in very low concentra-
tions and in different high Mr (Mr > 150000) forms
which have the immunoreactivity of the free basic fibro-
blast growth factor (Afr 14000-16000) (8, 23, 24). The
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biochemical nature of high MT forms of basic fibroblast
growth factor is not entirely clarified, while it seems that
at least some of them are conjugates of the growth factor
with the serum proteins which act as cleavage enzymes
(24). Furthermore, one of the characteristic features of
basic fibroblast growth factor is its affinity to bind to
heparin (7), while the binding of this growth factor to
other serum components (proteins) also seems probable.
This was also indicated by the preliminary results (not
presented) of the heparin affinity chromatography of the
sera samples used in the study (pooled according to the
groups). The high affinity of basic fibroblast growth
factor immunoreactivity for heparin (more than 90%)
was not influenced by the type of traumatic event.
Furthermore, membrane ultrafiltration of the pooled sera
samples indicate that the MT of the basic fibroblast
growth factor immunoreactivity in the sera was above
30 000. Hence, it seems that the basic fibroblast growth
factor immunoreactivity was represented by the higher
Mr forms of the growth factor and not by the free basic
fibroblast growth factor. However, further evaluation of
the biochemical characteristics of the serum basic fibro-
blast growth factor immunoreactivity is necessary. On
the other hand, since there was no major difference in
the storage and preservation of sera (including heparin
treatment during the initial post-traumatic phase) be-
tween the different groups of injured patients, it does
not seem that the medicaments significantly influence
the basic fibroblast growth factor immunoreactivity in
the sera of the patients. On the other hand, in accordance
with our results, the recent findings of Renfree et al. do
not indicate that traumatic brain injury is associated with
the phenomenon of heterotopic ossification by increased
growth promoting activity of the serum (25). Using an
in Vitro bioassay, these authors also observed a transient,
non-specific, growth inhibiting effect of the injured pa-
tient's sera in vitro during the initial post-traumatic week
(25). Thus, growth promoting as well as inhibiting activ-
ity of the serum of patients with traumatic brain injury
seems to be mediated by numerous factors whose activ-
ity and/or concentration are changed after injury. How-
ever, since these sera showed similar post-traumatic dy-
namic changes of the basic fibroblast growth factor im-
munoreactivity and similar effects on the L929 cell
growth, it was concluded that the phenomenon of en-
hanced osteogenesis in patients with traumatic brain in-
jury is related to the post-traumatic dynamic changes of
the serum basic fibroblast growth factor (11), but that
the relationship between these two phenomena does not
seem to be causative. More likely, the observed changes
of the serum basic fibroblast growth factor immunoreac-
tivity and enhanced osteogenesis are consequences of
some systemic reaction to the intensive injury, mani-
fested probably also by the increased toxicity of the se-
rum during the second week after injury. Further evalua-
tion of this hypothesis should not only aid the under-
standing the phenomenon of enhanced osteogenesis in
patients with traumatic brain injury but also the under-
standing of the systemic reaction to the injury and the
involvement of growth factors.
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